See more : InflaRx N.V. (IFRX) Income Statement Analysis – Financial Results
Complete financial analysis of RenovaCare, Inc. (RCAR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of RenovaCare, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Dongguang Chemical Limited (1702.HK) Income Statement Analysis – Financial Results
- Victory Giant Technology (HuiZhou)Co.,Ltd. (300476.SZ) Income Statement Analysis – Financial Results
- Crescera Capital Acquisition Corp. (CRECW) Income Statement Analysis – Financial Results
- WidePoint Corporation (WYY) Income Statement Analysis – Financial Results
- The Renewable Corporation (RNWB) Income Statement Analysis – Financial Results
RenovaCare, Inc. (RCAR)
About RenovaCare, Inc.
RenovaCare, Inc., a development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System, a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area. RenovaCare, Inc. has a strategic collaboration StemCell Systems GmbH for isolating and spraying self-donated stem cells to regenerate tissues and organs. The company was formerly known as Janus Resources, Inc. and changed its name to RenovaCare, Inc. in January 2014. RenovaCare, Inc. is based in Scottsdale, Arizona.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.49K | 32.79K | 39.85K | 51.13K | 13.77K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 919.42K | 463.29K | 153.71K | 0.00 | 66.43K |
| Cost of Revenue | 0.00 | 10.97K | 22.02K | 264.00 | 317.00 | 317.00 | 53.00 | 0.00 | 0.00 | 0.00 | 32.39K | 249.18K | 24.99K | 42.98K | 9.08K | 9.83K | 56.55K | 25.52K | 0.00 | 0.00 | 226.35K | 258.61K | -138.82K | 0.00 | 0.00 |
| Gross Profit | 0.00 | -10.97K | -22.02K | -264.00 | -317.00 | -317.00 | -53.00 | 0.00 | 0.00 | 0.00 | -12.89K | -216.39K | 14.86K | 8.15K | 4.69K | -9.83K | -56.55K | -25.52K | 0.00 | 0.00 | 693.06K | 204.68K | 292.53K | 0.00 | 66.43K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -66.14% | -660.00% | 37.29% | 15.94% | 34.06% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 75.38% | 44.18% | 190.31% | 0.00% | 100.00% |
| Research & Development | 0.00 | 3.20M | 4.13M | 745.95K | 368.95K | 574.09K | 309.50K | 281.22K | 975.67K | 0.00 | 0.00 | 36.85K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 2.20M | 5.54M | 2.94M | 1.64M | 2.12M | 1.59M | 1.04M | 1.16M | 628.55K | 248.60K | 536.09K | 0.00 | 312.16K | 0.00 | 7.95K | 47.68K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.29K | 34.16K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 2.20M | 5.54M | 2.94M | 1.64M | 2.12M | 1.59M | 1.04M | 1.16M | 628.55K | 248.60K | 536.09K | 215.46K | 312.16K | 190.69K | 27.24K | 81.84K | 56.54K | 133.67K | 579.71K | 845.67K | 558.77K | 967.59K | 747.99K | 355.02K |
| Other Expenses | 0.00 | 931.28K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.33K | 3.26K | 107.16K | 0.00 | 93.44K | 375.00 | 1.06K | 14.17K | 42.96K | 125.32K | 125.32K | 0.00 | 0.00 | 0.00 | 14.34K |
| Operating Expenses | 0.00 | 5.41M | 9.68M | 3.69M | 2.01M | 2.70M | 1.90M | 1.32M | 2.13M | 628.55K | 261.93K | 576.21K | 322.62K | 312.16K | 284.14K | 27.61K | 82.90K | 70.71K | 176.63K | 705.03K | 970.99K | 558.77K | 967.59K | 747.99K | 369.36K |
| Cost & Expenses | 0.00 | 5.41M | 9.68M | 3.69M | 2.01M | 2.70M | 1.90M | 1.32M | 2.13M | 628.55K | 261.93K | 825.39K | 347.61K | 355.15K | 293.22K | 27.61K | 82.90K | 70.71K | 176.63K | 705.03K | 1.20M | 817.38K | 828.77K | 747.99K | 369.36K |
| Interest Income | 0.00 | 6.42K | 128.76K | 332.24K | 22.45K | 3.14K | 1.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.30K | 2.93K | 1.86K | 2.75K | 1.58K | 5.82K | 16.04K | 36.13K | 86.60K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 135.27K | 996.65K | 180.70K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 375.00 | 1.06K | 0.00 | 0.00 | 614.00 | 518.00 | 0.00 | 0.00 | 38.33K | 71.06K |
| Depreciation & Amortization | 228.49K | 10.97K | 22.02K | 264.00 | 317.00 | 317.00 | 53.00 | 1.31K | 2.13K | 2.22 | 1.53K | 3.26K | 4.04M | -1.24M | 93.44K | 0.00 | -36.04K | 14.17K | 42.96K | 125.32K | 125.32K | 170.89K | 183.09K | 0.00 | 0.00 |
| EBITDA | 0.00 | -5.40M | -9.53M | -3.36M | -2.01M | -2.70M | -1.90M | -1.32M | -2.13M | -628.55K | -239.38K | -786.07K | 3.65M | -596.92K | -186.00K | -27.61K | -104.23K | -53.80K | -133.67K | -579.71K | -152.61K | -183.21K | -491.98K | -747.99K | -302.93K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,227.96% | -18,420.46% | 9,163.04% | -3,671.87% | -1,350.78% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -16.60% | -39.54% | -320.06% | 0.00% | -456.05% |
| Operating Income | 0.00 | -5.41M | -9.68M | -3.69M | -2.01M | -2.70M | -1.90M | -1.32M | -2.13M | -628.55K | -243.96K | -792.60K | -387.01K | -639.91K | -279.45K | -27.61K | -82.90K | -70.71K | -176.63K | -705.03K | -277.93K | -354.09K | -858.15K | -747.99K | -302.93K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,251.46% | -2,417.42% | -971.25% | -1,251.43% | -2,029.39% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -30.23% | -76.43% | -558.29% | 0.00% | -456.05% |
| Total Other Income/Expenses | 0.00 | 937.69K | 128.76K | 332.24K | -112.82K | -993.52K | -179.67K | 0.00 | 0.00 | 0.00 | 0.00 | 5.25M | -3.88M | 1.91M | 14.30K | 2.55K | 59.23K | 2.75K | 1.58K | 5.21K | 15.52K | 0.00 | 0.00 | 0.00 | 302.93K |
| Income Before Tax | 0.00 | -4.47M | -9.55M | -3.36M | -2.12M | -3.69M | -2.08M | -1.32M | -2.13M | -628.55K | -243.96K | 4.46M | -4.35M | 1.27M | -372.89K | 0.00 | -46.87K | -67.97K | -175.05K | -699.82K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,251.46% | 13,595.58% | -10,906.67% | 2,482.79% | -2,708.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -6.42K | -128.76K | 160.64K | 22.45K | 3.14K | 15.22K | -1.31K | -2.13K | 404.24K | 1.53K | -5.25M | -79.25K | -335.89K | -107.74K | 24.68K | -1.86K | 0.00 | 0.00 | 0.00 | -15.52K | -36.13K | 96.48K | 709.66K | 231.88K |
| Net Income | 0.00 | -4.47M | -9.42M | -3.36M | -2.12M | -3.69M | -2.08M | -1.32M | -2.13M | -1.03M | -243.96K | 4.46M | -4.27M | 1.27M | -265.15K | -24.68K | -45.00K | -67.97K | -175.05K | -699.82K | -262.40K | -317.97K | -771.55K | -709.66K | -231.88K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,251.46% | 13,595.58% | -10,707.79% | 2,482.79% | -1,925.56% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -28.54% | -68.63% | -501.95% | 0.00% | -349.08% |
| EPS | 0.00 | -0.05 | -0.11 | -0.04 | -0.03 | -0.05 | -0.03 | -0.02 | -0.03 | -0.02 | 0.00 | 0.07 | -0.07 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.02 | -0.03 | -0.07 | -0.03 | -0.01 |
| EPS Diluted | 0.00 | -0.05 | -0.11 | -0.04 | -0.03 | -0.05 | -0.03 | -0.02 | -0.03 | -0.02 | 0.00 | 0.07 | -0.07 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.02 | -0.03 | -0.07 | -0.03 | -0.01 |
| Weighted Avg Shares Out | 0.00 | 87.35M | 87.35M | 87.24M | 77.75M | 74.39M | 69.77M | 67.23M | 66.58M | 63.40M | 63.08M | 63.08M | 63.08M | 63.08M | 59.37M | 96.52M | 96.63M | 96.63M | 96.63M | 96.63M | 15.98M | 11.80M | 11.80M | 23.24M | 23.05M |
| Weighted Avg Shares Out (Dil) | 0.00 | 87.35M | 87.35M | 87.24M | 77.75M | 74.39M | 69.77M | 67.23M | 66.58M | 63.40M | 63.08M | 63.08M | 63.08M | 63.08M | 59.37M | 96.52M | 96.63M | 96.63M | 96.63M | 96.63M | 15.98M | 11.80M | 11.80M | 23.24M | 23.05M |
Rosen, Global Investor Counsel, Encourages RenovaCare, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important September 14 Deadline in Securities Class Action - RCAR
New York, New York--(Newsfile Corp. - August 11, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of RenovaCare, Inc. (OTC Pink: RCAR) between August 14, 2017 and May 28, 2021, inclusive...
Rosen, Global Investor Counsel, Encourages RenovaCare, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important September 14 Deadline in Securities Class Action - RCAR
New York, New York--(Newsfile Corp. - August 11, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of RenovaCare, Inc. (OTC Pink: RCAR) between August 14, 2017 and May 28, 2021, inclusive...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in RenovaCare, Inc. of Class Action Lawsuit and Upcoming Deadline - RCAR
New York, New York--(Newsfile Corp. - August 9, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against RenovaCare, Inc. ("RenovaCare" or the "Company") (OTC Pink: RCAR) and certain of its officers. The class action, filed...
RenovaCare Shareholder Alert
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In RenovaCare To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - August 6, 2021) - Faruqi & Faruqi, LLP, a leading national securities...
ROSEN, A TOP RANKED LAW FIRM, Encourages RenovaCare, Inc. Investors With Losses Over $100K to Secure Counsel Before Important September 14 Deadline in Securities Class Action - RCAR
New York, New York--(Newsfile Corp. - August 6, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of RenovaCare, Inc. (OTC Pink: RCAR) between August 14, 2017 and May 28, 2021, inclusive...
ROSEN, A TOP RANKED LAW FIRM, Encourages RenovaCare, Inc. Investors With Losses Over $100K to Secure Counsel Before Important September 14 Deadline in Securities Class Action - RCAR
New York, New York--(Newsfile Corp. - August 6, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of RenovaCare, Inc. (OTC Pink: RCAR) between August 14, 2017 and May 28, 2021, inclusive...
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against RenovaCare, Inc. (RCAR)
BENSALEM, Pa., Aug. 4, 2021 /PRNewswire/ -- Law Offices of Howard G.
ROSEN, SKILLED INVESTOR COUNSEL, Encourages RenovaCare, Inc. Investors With Losses Exceeding $100K to Secure Counsel Before Important September 14 Deadline in Securities Class Action – RCAR
NEW YORK--(BUSINESS WIRE)-- #RCAR--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of RenovaCare, Inc. (OTC: RCAR) between August 14, 2017 and May 28, 2021, inclusive (the “Class Period”) of the important September 14,...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in RenovaCare, Inc. of Class Action Lawsuit and Upcoming Deadline - RCAR
New York, New York--(Newsfile Corp. - August 1, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against RenovaCare, Inc. ("RenovaCare" or the "Company") (OTC Pink: RCAR) and certain of its officers. The class action, filed...
LOSS NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages RenovaCare, Inc. Investors with Losses Over $100K to Secure Counsel Before Important September 14 Deadline in Securities Class Action - RCAR
NEW YORK, July 30, 2021 /PRNewswire/ -- WHY: New York, N.Y., July 30, 2021.
Source: https://incomestatements.info
Category: Stock Reports